Christos Kyriakopoulos, MD discusses adding cabazitaxel to abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer.
Christos Kyriakopoulos, MD,
Advertisement
Articles by Christos Kyriakopoulos, MD,
Christos Kyriakopoulos, MD, discusses data from a phase 1/2 study of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5